UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2016-01, Vol.2 (1), p.1-12

2016

Volltextzugriff (PDF)

Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody

Alzheimer's research & therapy, 2016-04, Vol.8 (1), p.14, Article 14

2016

Volltextzugriff (PDF)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

JAMA neurology, 2021-04, Vol.78 (4), p.396

2021

Volltextzugriff (PDF)

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

Journal of neurology, neurosurgery and psychiatry, 2016-09, Vol.87 (9), p.993-999

2016

Volltextzugriff (PDF)

Translational Medicine Strategies in Alzheimer's Disease Drug Development

Handbook of Behavioral Neuroscience, 2019, Vol.29, p.349-362

2019

Volltextzugriff (PDF)

P1‐361: ASSESSING FUNCTION IN EARLY AD: ANALYSIS OF ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) 3 DATA FOR THE FINANCIAL CAPACITY INSTRUMENT SHORT FORM (FCI‐SF)

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_8), p.P432-P433

2018

Volltextzugriff (PDF)

ASSESSING FUNCTION IN EARLY AD: ANALYSIS OF ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) 3 DATA FOR THE FINANCIAL CAPACITY INSTRUMENT SHORT FORM (FCI-SF)

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P432-P433

2018

Volltextzugriff (PDF)

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease

Alzheimer's research & therapy, 2014-01, Vol.6 (2), p.16-16

2014

Volltextzugriff (PDF)

F4‐03‐04: RETROFITTING EXISTING TOOLS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM

Alzheimer's & dementia, 2014-07, Vol.10, p.P244-P245

2014

Volltextzugriff (PDF)

The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)

Alzheimer's & dementia, 2024-01, Vol.20 (1), p.695-708

2024

Volltextzugriff (PDF)

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

JAMA neurology, 2023-06, Vol.80 (6), p.614

2023

Volltextzugriff (PDF)

White matter in different regions evolves differently during progression to dementia

Neurobiology of aging, 2019-04, Vol.76, p.71-79

2019

Volltextzugriff (PDF)

Medical Image Imputation From Image Collections

IEEE transactions on medical imaging, 2019-02, Vol.38 (2), p.504-514

2019

Volltextzugriff (PDF)

Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3

Frontiers in neuroinformatics, 2019-02, Vol.13, p.2-2

2019

Volltextzugriff (PDF)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms

Alzheimer's & dementia, 2019-02, Vol.15 (2), p.194-204

2019

Volltextzugriff (PDF)

Functional signature of conversion of patients with mild cognitive impairment

Neurobiology of aging, 2019-02, Vol.74, p.21-37

2019

Volltextzugriff (PDF)

Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease

Alzheimer's & dementia, 2013-03, Vol.9 (2), p.123-131.e1

2013

Volltextzugriff (PDF)

P4‐181: INITIAL LEARNINGS FROM SCREENING STRATEGIES IN THE BAN 2401‐G000‐201 TRIAL: AN EARLY ALZHEIMER'S DISEASE STUDY

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_23)

2014

Volltextzugriff (PDF)

A concise and persistent feature to study brain resting‐state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative

Human brain mapping, 2019-03, Vol.40 (4), p.1062-1081

2019

Volltextzugriff (PDF)

Evaluating trajectories of episodic memory in normal cognition and mild cognitive impairment: Results from ADNI

PloS one, 2019-02, Vol.14 (2), p.e0212435-e0212435

2019

Volltextzugriff (PDF)

PHARMACOLOGICAL CHARACTERIZATION OF BAN2401-MEDIATED Aβ PROTOFIBRIL CLEARANCE BY MICROGLIA

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P625-P626

2017

Volltextzugriff (PDF)

THE FINANCIAL CAPACITY INSTRUMENT–SHORT FORM IS A NOVEL, PERFORMANCE-BASED MEASURE THAT MAY HELP DIFFERENTIATE MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE POPULATIONS IN CLINICAL TRIALS

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P264-P265

2017

Volltextzugriff (PDF)

Composite measures in Alzheimer’s disease clinical trials: How an in-study data quality program ensures immediate and ongoing quality of the sum of their parts

Alzheimer's & dementia, 2015-07, Vol.11 (7), p.P903-P903

2015

Volltextzugriff (PDF)

P4‐310: Composite measures in Alzheimer's disease clinical trials: How an in‐study data quality program ensures immediate and ongoing quality of the sum of their parts

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_19), p.P903-P903

2015

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Englisch
(78)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(25)
Alzheimer's Disease
(24)
Neurology
(23)
Neurosciences & Neurology
(18)
Humans
(16)
Male
(14)
Neuroimaging
(14)
Aged
(13)
Female
(13)
Neurosciences
(12)
Dementia
(10)
Medical Imaging
(10)
Alzheimer Disease - Diagnostic Imaging
(8)
Biomarkers
(8)
Magnetic Resonance Imaging
(8)
Brain
(7)
Clinical Neurology
(7)
Cognitive Ability
(7)
Dementia Disorders
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease

Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain

Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

Translational Medicine Strategies in Alzheimer's Disease Drug Development

P1‐361: ASSESSING FUNCTION IN EARLY AD: ANALYSIS OF ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) 3 DATA FOR THE FINANCIAL CAPACITY INSTRUMENT SHORT FORM (FCI‐SF)

ASSESSING FUNCTION IN EARLY AD: ANALYSIS OF ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) 3 DATA FOR THE FINANCIAL CAPACITY INSTRUMENT SHORT FORM (FCI-SF)

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease

F4‐03‐04: RETROFITTING EXISTING TOOLS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM

The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

White matter in different regions evolves differently during progression to dementia

Medical Image Imputation From Image Collections

Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms

Functional signature of conversion of patients with mild cognitive impairment

Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease

P4‐181: INITIAL LEARNINGS FROM SCREENING STRATEGIES IN THE BAN 2401‐G000‐201 TRIAL: AN EARLY ALZHEIMER'S DISEASE STUDY

A concise and persistent feature to study brain resting‐state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative

Evaluating trajectories of episodic memory in normal cognition and mild cognitive impairment: Results from ADNI

PHARMACOLOGICAL CHARACTERIZATION OF BAN2401-MEDIATED Aβ PROTOFIBRIL CLEARANCE BY MICROGLIA

THE FINANCIAL CAPACITY INSTRUMENT–SHORT FORM IS A NOVEL, PERFORMANCE-BASED MEASURE THAT MAY HELP DIFFERENTIATE MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE POPULATIONS IN CLINICAL TRIALS

Composite measures in Alzheimer’s disease clinical trials: How an in-study data quality program ensures immediate and ongoing quality of the sum of their parts

P4‐310: Composite measures in Alzheimer's disease clinical trials: How an in‐study data quality program ensures immediate and ongoing quality of the sum of their parts

Suchergebnisse filtern